VASOGEN REPORTS RESULTS OF ACCLAIM TRIAL

A A

Vasogen has reported that the pivotal Phase III ACCLAIM trial of its Celacade technology in patients with advanced chronic heart failure has reached its pre-specified objective of 701 primary endpoint events. Achieving this key objective allows for the 2,400-patient, multinational ACCLAIM trial to be completed by the year's end, with results of the study to be made available following data analysis.

The double-blind, placebo-controlled ACCLAIM trial is intended to definitively assess the impact of Celacade technology on reducing the risk of death and cardiovascular hospitalizations in patients with advanced chronic heart failure and to support regulatory approval and market introduction in North America and Europe.